NICE makes J&J's Tremfya more accessible in England and Wale...

NICE has updated its recommendations for NHS use of Johnson & Johnson's IL-23 inhibitor Tremfya in the treatment of psoriatic arthritis (PsA), expanding the pool of patients eligible fo

J&J's Tremfya to join crowded psoriatic arthritis market aft...

The FDA has approved a label extension for Johnson & Johnson’s Tremfya (guselkumab) in psoriatic arthritis, the first drug from the IL-23 class to gain a foothold in this indication. 

J&J filing aims Tremfya at crowded psoriatic arthritis marke...